Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

Inclusion Criteria: * Histologically confirmed epithelial ovarian cancer, primary fallopian or primary peritoneal cancer. * Platinum resistant epithelial ovarian cancer treated with at least two different previous chemotherapeutic regimens * Progression on previous treatment. Previous treatment with bevacizumab is allowed. * Measurable disease by the RECIST 1.1 criteria or evaluable by the GCIG CA-125 criteria. * Age ≥ 18 years. * Performance status 0-2. * Adequate bone marrow function, liver function, and renal function (within 7 days prior to inclusion): * WBC ≥ 3.0 x 10\^9/l or neutrophils (ANC) ≥ 1.5 x 10\^9/l * Platelet count ≥ 100 x 10\^9/l * Hemoglobin ≥ 6 mmol/l * Serum bilirubin \< 2.0 x ULN * Serum transaminase ≤ 2.5 x ULN * Serum creatinine ≤ 1.5 ULN * Urine dipstick for protein \< 2+. If the dipstick shows protein ≥ 2+, 24 hour urine testing must be performed and show protein contents \< 1 g. * Written informed consent Exclusion Criteria: * Other malignant disease within 3 years prior to inclusion in the study, except curatively treated basal cell or squamous cell carcinoma of the skin. * Other experimental therapy or participation in another clinical trial within 28 days prior to treatment initiation. * Intestinal infiltration or infiltration in major blood vessels at the discretion of the treating physician. * Underlying medical disease not adequately treated (diabetes, cardiac disease). * Uncontrolled hypertension (BP \> 150/100 despite antihypertensive treatment). * Surgery including open biopsy, within 4 weeks prior to first dose of bevacizumab. * Cerebral vascular attack, transient ischemic attack or subarachnoid hemorrhage within 6 months before start of treatment. * Clinical significant cardiovascular disease, including: * Myocardial infarction or unstable angina within 6 months before start of treatment * New York Heart Association (NYHA) class ≥ 2 * Poorly controlled cardiac arrhythmia despite medication * Peripheral vascular disease grade ≥ 3 * Allergy to active substance or any of the auxiliary agents * Bleeding tumor * Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at screening is mandatory. * Fertile patients not willing to use effective methods of contraception during treatment and for 6 months after the end of treatment.